Aklief (Trifarotene) Patent Expiration, LOE Window & CMS Spending

Aklief (Trifarotene) by Galderma Laboratories: FDA Orange Book core substance LOE 2031-07-19 (last listed 2033-05-30), 0 AB generics, $334K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGalderma Laboratories
FDA Application & PathwayN211527 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-07-19
Last Listed Patent or Exclusivity Date2033-05-30
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$334K
2024 Medicare Part D Spend$260K
2024 Medicaid Spend$74K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel